Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927114" target="_blank" >RIV/00064173:_____/24:43927114 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/24:43927114
Result on the web
<a href="https://doi.org/10.1111/ijd.17285" target="_blank" >https://doi.org/10.1111/ijd.17285</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ijd.17285" target="_blank" >10.1111/ijd.17285</a>

Result language
angličtina
Original language name
Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma
Original language description
Immunotherapy with checkpoint inhibitors is considered the golden standard not only for adjuvant setting of high-risk melanoma (stage III/IV) but also for palliative treatment of advanced melanoma. In spite of the high efficacy of this therapy, in at least 50% of patients with high-risk melanoma in stage III or with advanced melanoma in stage IV, a failure of therapy occurs. A single-center prospective observational study was conducted with 18 adults with advanced malignant melanoma after previous failure of anti-PD-1 +/- anti-CTLA-4 treatment in the adjuvant or palliative setting (Table 1). This study received the approval of the Ethics Committee, and all subjects provided written informed consent. Patients were enrolled between January 1, 2021, and December 31, 2023. Lenvatinib and pembrolizumab combination therapy was initiated, where lenvatinib was administered in a dose of 20 mg per day, and pembrolizumab was applied in a flat dose of 200 mg IV infusion every 3 weeks. The objective response rate (ORR-complete response/CR + partial response/PR) was the primary endpoint. The progression-free survival (PFS), the overall survival (OS), and the safety profiles were the secondary endpoints.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)